Development of novel therapeutic agents is needed to address the problems of locally recurrent, metastatic, and advanced hormone-refractory prostate cancer. We have constructed a novel complex adenovirus (Ad) vector regulation system that incorporates both the prostate-specific ARR2PB promoter and a positive feedback loop using the TRE promoter to enhance gene expression. This regulation strategy involves the incorporation of the TRE upstream of the prostate-specific ARR2PB promoter to enhance its activity with Tet regulation. The expressions of both GFP and tTA were placed under the control of these TRE-ARR2PB promoters, so that in the cells of prostate origin a positive feedback loop would be generated. This design greatly enhanced GFP reporter expression in prostate cancer cells, while retaining tight control of expression in nonprostate cancer cells, even at an MOI as high as 1000. This novel positive feedback loop with prostate specificity (PFLPS) regulation system we have developed may have broad applications for expressing not only high levels of toxic proteins in cancer cells, but alternatively could also be manipulated to regulate essential genes in a highly efficient conditionally replicative adenovirus vector specifically directed to prostate cancer cells. The PFLPS regulation system, therefore, serves as a promising new approach in the development of both a specific and effective vector for cancer gene therapy.
Introduction
For 2003, it was estimated that 220 900 new cases of prostate cancer would be diagnosed, and 28 900 men would die from this disease. 1 Although the 5-year relative survival rate for patients with diagnoses in the local and regional stages is 100%, 1 approximately 30% of patients treated for localized disease relapse. 2 In addition, current treatments of localized prostate cancer are not without complications. [3] [4] [5] [6] Radical prostatectomy involves undergoing major surgery and often results in temporary to permanent complications such as incontinence and impotence. 3, 4, 6 In addition, not all cases of local disease can be treated by the traditional local curative approaches due to local invasion of nearby tissues and a loss of differentiation. Locally advanced tumor growth can lead to bladder outlet obstruction, base of bladder invasion, urethral obstruction, and local pain and discomfort in these patients. 7 Therefore, there is clearly a need to investigate alternative treatment strategies to expand the arsenal of locally advanced prostate cancer treatment options.
One such treatment alternative is the use of gene therapy vectors to specifically eliminate prostate cancer cells utilizing proapoptotic genes including Fas ligand (FasL), tumor necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL), or Bax. As many of these cancer gene therapy strategies involve the induction of a toxic gene product to eliminate the cancer cells, it is important to localize that transgene expression to target cells only. Incorporation of tissue-specific promoters to localize transgene expression has been utilized for several cytotoxic cancer gene therapy vectors that have been investigated in clinical trials. [8] [9] [10] One tissue-specific promoter that has shown promise as a candidate promoter for driving cytotoxic transgenes for the development of a prostate cancer gene therapy vector is the ARR2PB promoter. This synthetically derived, prostate-specific promoter was developed from regulatory elements from the rat probasin promoter. [11] [12] [13] This promoter demonstrated good prostate-specific regulation both in vitro and in transgenic mice. [13] [14] [15] [16] Although the ARR2PB promoter includes two androgen response regions (ARRs) that greatly enhance prostate-specific transgene expression, induced transgene expression from ARR2PB, like that from most mammal-derived tissue-specific promoters, still tends to be significantly weaker than that induced by virus-derived promoters, such as the human cytomegalovirus intermediate/early (hCMVie) promoter. 16 Previously, in our lab, we attempted to enhance the transcriptional activity of the ARR2PB promoter by combining the ARR2PB promoter with elements of the tetracycline (Tet) regulatory system [17] [18] [19] in a single complex adenoviral vector. 16 While this complex vector, known as the Ad/FasL-GFP PS/TR vector, was successful in enhancing the induced levels of a Fas ligand-green fluorescent protein (FasL-GFP) fusion protein in prostate cancer cells, this combination of regulatory elements also resulted in a decrease in prostate specificity. This reduction in specificity may be the result of an inherent limitation of the tetracycline responsive element (TRE) promoter from which some transgene expression still occurs even under uninduced conditions (ie, presence of excess doxycycline (dox, a tetracycline analog) in the case of the Tet activator (tTA); or the absence of dox in the case of the reverse Tet activator (rtTA)) in transient cell transduction systems like adenovirus; this has been observed by our group as well as by others. [18] [19] [20] Such leaky expression could be quite detrimental in terms of a cancer gene therapy vector. If the transgene expression is not tightly regulated, toxic protein could be nonspecifically expressed in several nontarget cells, leading to unwanted destruction of noncancerous tissues.
The ideal Ad vector for prostate cancer gene therapy would be one that is both prostate-specific, yet still elicits highly induced expression of a toxic protein. We attempt to achieve this goal by developing a novel prostatespecific regulatory system known as the positive feedback loop with prostate specificity, or PFLPS, system. This system, incorporated into a replication-incompetent Ad vector deleted in E1, E3, and E4 (except for E4orf6), is composed of a unique arrangement of the Tet-off regulatory system elements in combination with the ARR2PB promoter. It is our belief that the low but significant nonspecific expression induced in our Ad/ FasL-GFP PS/TR vector may have been as a result of basal activity of the minimal CMV promoter incorporated in the TRE promoter. To circumvent this possible source of 'leaky' expression, we have incorporated both a Tet responsive element upstream of the ARR2PB promoter along with a positive feedback loop to enhance prostatespecific transgene expression. This design ensures prostate-specific expression of both tTA and the gene of interest (GOI), while establishing a positive feedback loop in which prostate-specific expression of tTA further induces expression of itself as well as the GOI.
In this study, we develop and characterize our new PFLPS regulation system both in the context of plasmid constructs as well as in a single complex Ad vector. The PFLPS system, when cloned into plasmid vectors, demonstrated both prostate specificity and high levels of induced expression of GFP. The GFP expressed from the PFLPS plasmids was found to be even greater than that induced by the nonspecific Tet-regulated control. When incorporated into a complex Ad vector, the PFLPS system once more demonstrated highly induced, prostate-specific expression. These levels could be induced with dihydrotestosterone (DHT) to levels higher than those induced by the nonspecific Tet-regulated control. In addition, preservation of prostate specificity by PFLPS was demonstrated by analysis of A549, HeLa, and HepG2 cell lines infected with Ad/GFP PFLPS vector by both RT-PCR, as well as by analysis of GFP expression at high multiplicities of infection (MOIs). Prostate specificity of the PFLPS system was retained even at MOI 1000, thereby demonstrating a high level of control in the PFLPS vector. The PFLPS regulation system, therefore, serves as a promising new approach in the development of both a specific and effective vector for future applications in the field of cancer gene therapy.
Results

Design of the PFLPS regulation system
In order to augment the activity of the ARR2PB promoter, we have developed a novel PFLPS regulation system that incorporates both the components of the Tetoff regulation system as well as the ARR2PB promoter, in a positive feedback loop. The design of the PFLPS regulation system as cloned into Ad5 vector deleted in E1, E3, and E4 (except for E4orf6) is depicted in Figure 1 along with control Ad vectors, Ad/GFP TET , which expresses GFP under the control of the traditional Tetoff regulatory system, and Ad/C.LacZ, which expresses b-galactosidase under the control of the hCMVie promoter.
The PFLPS components were first cloned into plasmid vectors, incorporating the reporter gene, green fluorescent protein (GFP), as the gene of interest (Figure 2a ). Special consideration was made in the construction of this complex rAd vector, based upon our previous findings regarding interference from the E1a enhancer. As we had previously found that the basal activity of both the TRE and the ARR2PB promoters was significantly affected by interference from the E1a enhancer, 21 we designed the Ad/GFP PFLPS vector so that the TRE-ARR2PB.GFP cassette was away from the E1 region by placing it near the right ITR (see the right end plasmid, pRAd 2 T2Pb.GFP.B; Figure 2a ). Meanwhile, we also placed the TRE-ARR2PB.tTA cassette in reverse orientation near the left ITR so that its promoter was also away from the E1a enhancer region (see the left-end plasmid, pLAd(T2Pb.tTA.S) r ; Figure 2a ). The theoretical mechanism of action of the PFLPS regulation system is diagrammed in Figures 2b and c. By having both tTA and GFP under the control of the TRE-ARR2PB promoter, this not only initiates a positive feedback loop in prostate cancer cells but also maintains the PFLPS system's prostate specificity in cells of non-prostate origin.
Levels of prostate-specific expression induced by PFLPS are greater than those induced by the nonspecific, Tet-regulated control
In order to determine the activity of the PFLPS system, the system was first tested by transfection of plasmid vectors into prostate and non-prostate cell lines. LNCaP, a prostate cancer cell line, and U343MG, a brain tumor cell line (serving as non-prostate control cell line), were seeded in 24-well plates 1 day prior to being cotransfected with either Tet plasmids (pUHD 15-1 plus pRAd 2 T.GFP.B), ARR2PB plasmid (pRAd 2 2Pb.GFP plus empty vector), PFLPS plasmids (pLAd(T2Pb.tTA.S) r plus pRAd 2 T2Pb.GFP.B) or empty vector. At 3 days posttransfection, the media was aspirated and cells were lysed with 0.5% Triton X-100 solution and assayed for GFP expression as described in Materials and methods. As shown in Figure 3 , the PFLPS plasmids demonstrated high levels of prostate-specific induction of GFP expression in LNCaP cells, while the levels of GFP expression We assembled vector genomes in vitro using pLAd and pRAd shuttle vectors as described previously. 22, 23 The resulting rAd vectors are E1-deleted and have a deletion in the E3 region (E3 promoter is retained). They also lack all of the E4 ORFs, except orf6, which is expressed from the E4 promoter.
Novel PFLPS regulation system J Woraratanadharm et al in U343MG cells were similar to empty vector control. In addition, GFP induction in LNCaP cells was significantly higher than that induced by the nonspecific, Tetregulated positive control ( Figure 3 ), and at least 3.5 times higher than the ARR2PB promoter alone. The level of GFP expression from the ARR2PB plasmid in LNCaP cells was approximately 78.4% that of the Tet plasmid pair. This activity from the ARR2PB plasmid is likely higher than expected because positive GFP induction only requires transfection with a single plasmid, whereas positive GFP expression induction by the Tet plasmids (and the PFLPS plasmids, as well) requires simultaneous transfection of a cell by two separate plasmids. U343MG cells were chosen as the non-prostate control cell line for these studies because both U343MG's optimal transfection conditions and its transfection efficiency are similar to that of LNCaP.
The positive results obtained in Figure 3 demonstrated the potential of the PFLPS system at the plasmid level and therefore justified the cloning of the PFLPS components into an Ad5 vector, utilizing methods described previously. [22] [23] [24] The resulting complex Ad vector, known as Ad/GFP PFLPS , was propagated and purified for characterization in in vitro studies. To determine the prostate specificity of Ad/GFP PFLPS vector, its GFP expression was first characterized in two prostate cancer cell lines, LNCaP and 22RV1 (mouse prostate cancer cell line), and a non-prostate cell line, U251MG. Since the ARR2PB promoter is inducible by androgen (eg, DHT), both LNCaP and 22RV1 cell lines were chosen specifically because they are two of the few prostate cancer cell lines available that express functional androgen receptor.
Infection of LNCaP, 22RV1, and U251MG with Ad/ GFP PFLPS demonstrated high levels of GFP induction in the prostate cancer cell lines without a loss in prostate specificity, as the levels of GFP expression in the U251MG cells were similar to background (Figures 4a  and b) . These data were represented in both raw units, as taken from the fluorescence plate reader (FLUOstar; BMG Labtechnologies) (Figure 4a ), as well as in percent GFP expression, setting infection with the Tet-regulated Ad/GFP TET vector at 100% (Figure 4b ). Both representations of the infection demonstrated that GFP induction in LNCaP cells by Ad/GFP PFLPS was significantly higher than that seen with the nonspecific Ad/GFP TET vector; this supports the transfection results seen in Figure 3 .
GFP induction from PFLPS is restricted to only cells of prostate origin
As a positive feedback loop has been incorporated in the PFLPS vector design, minute levels of nonspecific transgene expression could initiate the positive feedback loop in nontarget cells. Therefore, it is important to verify that prostate specificity has been retained in the PFLPS regulation system. In order to determine if the Ad/ GFP PFLPS vector is not only highly induced in prostate cancer cells but also retains prostate specificity when transduced into non-prostate cells, LNCaP and U251MG were infected at MOIs 0, 10, 100, and 1000 in the presence of 30 nM DHT and assayed for GFP expression. Both the Ad/GFP PFLPS vector and the positive control Ad/GFP TET vector demonstrated dose-dependent GFP expression Novel PFLPS regulation system J Woraratanadharm et al in LNCaP cells (Figure 5a ), and in addition further supported the data shown in Figures 3 and 4 that PFLPSinduced GFP expression is significantly higher than that induced by the Tet-regulatory system. On the other hand, only the Ad/GFP TET vector demonstrated dose-dependent GFP expression in U251MG cells. In addition, GFP induction by Ad/GFP PFLPS vector was undetectable in U251MG, even at MOI 1000 (Figure 5b) , demonstrating that the transgene expression from the PFLPS regulatory system is tightly controlled.
To characterize the prostate specificity, Ad/GFP PFLPS vector was transduced into three additional non-prostate cell lines (A549, HeLa, and HepG2). Since LNCaP cells tend to be highly transducible and in addition more efficiently express GFP when compared to the other cell lines tested, the non-prostate cell lines were infected at MOI 1000, while LNCaP was transduced at MOI 100. These cells were then assayed for GFP expression. Remarkably, even in the presence of DHT and at MOI 1000, GFP expression from the non-prostate cell lines was undetectable following transduction with Ad/GFP PFLPS vector, while the same vector induced higher than Ad/GFP TET levels of GFP expression in LNCaP cells (Figure 6a) .
As an additional, more stringent test of specificity, RT-PCR for GFP expression was also conducted on the same cell lines assayed in Figure 6a to determine relative mRNA transcription following Ad/GFP PFLPS infection. In this analysis, total mRNA was purified from vectortransduced cells 2 days post-infection and levels of reporter gene induction were determined by PCR analysis of cDNA for GFP. Relative levels of GFP Novel PFLPS regulation system J Woraratanadharm et al induction among different cell lines were standardized in relation to b-actin transcription levels. The RT-PCR analyses demonstrated that, although the transduction efficiency tended to vary from cell line to cell line (as seen in Figure 6a ), the data still indicated retention in prostate specificity of the PFLPS regulatory system (Figure 6b ).
Discussion
When developing gene therapy vectors expressing toxic transgenes such as FasL, several factors must be considered in the vector design. First, in order to prevent transgene-related systemic cytotoxicity, toxic gene expression must be restricted to only the cancer cell targets. Secondly, while the safety of the vector is important, highly induced expression in the target cells must not be compromised in the process since, often, a major limitation of gene therapy vectors is insufficient gene expression to initiate a therapeutic effect. Conversely, highly induced transgene expression must also retain specificity in order to preserve the safety of the vector. Finally, it is important to consider the possibility that the vector's propagating cell line (eg, HEK293 cells for rAd vectors) may also be susceptible to the effects of the toxic transgene. Therefore, it is necessary to also prevent transgene expression during the propagation and production of the gene therapy vector. For these reasons, it is important to consider regulation of transgene expression when designing cancer gene therapy vectors.
Strategies for restricting toxic gene expression both temporally and spatially include incorporating tissue-or cancer-specific promoters and drug-inducible or -repressible regulation systems. 9, 10, 16, 19, 25, 26 In the present study, we describe a strategy for inducing potent prostatespecific transgene expression incorporating elements of the Tet-off regulation system with the prostate-specific ARR2PB promoter. This regulation system demonstrates an enhancement of the transcriptional activity of the ARR2PB promoter without losing specificity. The PFLPS regulation system has three characteristics that make it unique: (1) the newly developed TRE-ARR2PB promoter; (2) induction of a prostate-specific positive feedback loop; and (3) the cloning of the entire system into a single complex recombinant Ad vector, thus preventing the need for co-infection with two separate Ad vectors. By combining the prostate specificity of the ARR2PB promoter with the Tet responsive element, we were able to establish a PFLPS regulatory system that demonstrated highly induced levels of prostate-specific expression. Interestingly, activity from the PFLPS regulation system was at least 1.5-fold higher than the highly induced Tet-regulated system. This type of activity from a tissue-specific gene therapy vector is quite unusual and sets an exciting new precedent in the field of gene therapy. Normally, one would expect that the consequence of such highly induced expression from a tissue-specific vector would be a loss in tissue specificity. However, this was not the case. Even at an MOI as high as 1000, the Ad/GFP PFLPS vector demonstrated a retention in prostate specificity.
Notably, the Ad/GFP PFLPS vector demonstrated little GFP expression in HepG2 cells at MOI 1000. This lack of transgene expression in liver-derived cells is significant since Ad vectors typically accumulate in the liver following systemic injection. Therefore, liver toxicity due to nonspecific transgene induction may become less of an issue when the PFLPS system is utilized to control the expression of toxic transgenes. We plan on confirming this in future studies.
In this study, we have investigated the activity of a novel transgene regulation system that, in future studies, will regulate the proapoptotic FasL gene. Our current studies were conducted utilizing GFP as a reporter; however, when designing gene therapy vectors that will be expressing toxic transgenes, it is important to consider that production of such vectors involves special manipulations that may not be necessary when propagating vectors expressing nontoxic genes. For instance, merely expressing FasL, or any other stand-alone toxic transgene, from a constitutive promoter such as the hCMVie promoter is not a viable option. Since the toxic transgene would lethally damage the propagating cell line (HEK293) before any viral particles could be formed, the resultant vector would likely be either low in titer or favor selection for replication-competent mutant vectors. For this reason, our first-generation FasL-GFP vector, Ad/FasL-GFP TET , incorporated the Tet-off regulation system to express the FasL-GFP fusion 24 and was propagated in the presence of doxycycline in 293CrmA cells (HEK293 cells stably transfected with Cowpox virus (Chordopoxvirinae) cytokine response modifer A (CrmA) 24 ) to minimize Fas-mediated apoptosis of the propagating cell line. Consequently, we have incorporated prostate specificity into the PFLPS vector to not only reduce systemic toxicity in the gene therapy recipient but also to aid in the production of a high titer Ad vector expressing a toxic transgene.
Future applications of the PFLPS regulation system include organ-restricted cancer gene therapy applications, general gene therapy applications, recombinant vaccine technology, and transgenic mouse models. As intimated with the discussion of our Ad/FasL-GFP TET vector, incorporating FasL-GFP into PFLPS may serve as a promising vector for prostate cancer gene therapy as we have previously demonstrated this transgene's efficacy in eliminating Fas-resistant prostate cancer cells. 27 Other candidate toxic transgenes for the gene therapy treatment of cancers include TRAIL, [28] [29] [30] Bax, 15, [31] [32] [33] and suicide genes such as herpes simplex virus thymidine kinase (HSV-tk). [34] [35] [36] [37] Additionally, conditionally replicating adenovirus (CRAd) vectors have recently gained attention as a potential gene therapy vector for the treatment of cancers. [38] [39] [40] Incorporation of prostate-specific regulation of Ad early genes using the PFLPS regulation system could potentially produce a potent yet safe vector for the treatment of prostate cancers.
The PFLPS regulation system is not restricted to only the gene therapy treatment of prostate cancers; however, as the positive feedback loop concept could be transferred to other tissue types by simply incorporating different tissue-specific promoters, it thereby expands its potential utility to include gene therapy of other cancers and molecular genetic applications other than cancer, such as the gene therapy treatment of genetic disorders, development of gene-based vaccines expressing immunogenic bacterial or viral antigens, and development of new mouse models that require highly Novel PFLPS regulation system J Woraratanadharm et al induced, organ-restricted expression of a particular gene of interest. Finally, the effective transcriptional regulation afforded by PFLPS could be combined with current methods of transductional regulation including manipulation of Ad fiber knob [41] [42] [43] [44] [45] [46] [47] and use of bi-specific antibodies 38, [48] [49] [50] [51] to further improve the targeting of gene therapy vectors to specific cell types and therefore increase the specificity and the safety of the vectors.
In conclusion, we have developed and characterized a novel transcriptional regulatory system that demonstrates highly induced, prostate-specific expression without a loss in specificity. Such a regulation system could be potentially altered to include tissue-or cancer-specific promoters in the place of the ARR2PB promoter as well as any desired transgene in place of GFP, and thus is ideal for several molecular genetic and gene therapeutic applications that require highly induced, organrestricted expression of a particular gene of interest. This transcriptional regulation can also be combined with transductional regulation systems to increase the specificity and the safety of current gene therapy vectors. The PFLPS regulation system, therefore, serves as an exciting new strategy for the transcriptional regulation of therapeutic genes for future molecular genetic and therapeutic applications.
Materials and methods
Cell lines
HEK293 (human embryonic kidney), LNCaP (human prostate cancer), and 22RV1 (mouse prostate cancer) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). U343MG and U251MG (brain tumor) cell lines were obtained from the Brain Tumor Research Center Tissue Bank (Department of Neurological Surgery, UCSF, San Francisco, CA, USA). All cell lines were maintained in media supplemented with 10% cosmic calf serum (CCS, HyClone, Logan, UT, USA), with HEK293 being maintained in DMEM, LNCaP and 22RV1 being maintained in RPMI, and U343MG and U251MG being maintained in MEM.
Construction of plasmid vectors
The pUHD10-3 (containing the TRE promoter) and pUHD15-1 (containing the tTA gene) were generously provided by Hermann Bujard (Center for Molecular Biology, University of Heidelberg, Heidelberg, Germany). The ARR2PB (0.45 kb) promoter was developed in the laboratory of Robert J Matusik (Department of Cell Biology, Vanderbilt University Medical Center, Nashville, TN, USA), who contributed the pARR2PB.PolI.TRZ-SK vector. ARR2PB is based on the minimal probasin promoter with a duplicated probasin ARR upstream of it. 12 Construction of pLAd-CMV, pLAd-mcs, and pRAd-T.GFP vectors has been described previously. 24 We excised the ARR2PB promoter from pARR2PB.PolI.TRZ-SK and the tTA gene from pUHD15-1 and cloned them into pLAd-mcs to generate pLAd-2Pb.tTA. 16 We excised the ARR2PB.tTA cassette from pLAd-2Pb.tTA and cloned it back, but in reverse orientation to generate pLAd(2Pb.tTA) r . We excised the TRE promoter from pUHD10-3 and cloned it upstream of the ARR2PB promoter in the pLAd(2Pb.tTA) r construct to generate pLAd(T2Pb.tTA.S) r (see Figure 2a) . We cloned the TRE-ARR2PB.tTA cassette in reverse orientation near the left ITR so that its promoter is away from the E1a enhancer region, since we had previously found that the basal activities of both the TRE promoter and the ARR2PB promoter were significantly affected by interference from the E1a enhancer. 21 To construct the pRAd 2 T2Pb.GFP.B plasmid (see Figure 2a) , we excised the TRE-ARR2PB promoter from pLAd(T2Pb.tTA.S) and cloned it in the place of the TRE promoter in pRAd 2 T.GFP.B (a plasmid closely related to pRAd-T.GFP).
Construction of recombinant adenoviral vectors
Construction of Ad/C.LacZ. and Ad/GFP TET has been described previously. 24 pLAd(T2Pb.tTA.S) r and pRAd 2 T2Pb.GFP.B plasmids were digested with SwaI and SpeI and ligated to an Ad5 genome backbone (Ad5sub360SR) digested on both ends with XbaI. The assembly of the Ad/GFP PFLPS vector genome was constructed as described previously. 22, 23 All Ad vectors were based on Ad5sub360SR, which contains deletions in E3 and all E4 ORFs, with the exception of ORF6.
Propagation and titering of recombinant adenovirus vectors
All vectors were propagated in HEK293 cells, using standard procedures. 22, 24 Briefly, HEK293 cells, which provide Ad5 E1a and E1b functions in trans, were transfected with the ligation mixture containing the recombinant adenovirus (rAd) vector DNA using Fugene 6 transfection reagent (Roche, Indianapolis, IN, USA) and manufacturer's instructions. Transfected cells were maintained until adenovirus-related cytopathic effects (CPE) were observed (typically 7-14 days posttransfection), at which point the cells were collected. Vector propagation and amplification were then achieved by standard techniques. Briefly, adenoviral lysates from 24 150 mm 2 plates were banded twice on CsCl gradients and desalted twice with a PD-10 size exclusion column (Amersham Scientific, Piscataway, NJ, USA) into HEPES-buffered saline (HBS; 21 mM HEPES, 140 mM NaCl, 5 mM KCl, 0.75 mM Na 2 HPO 4 Á 2H 2 O, and 0.1% (w/v) dextrose; adjust pH with NaOH to 7.5; and filter sterilize) containing 5% glycerol, and stored at À701C. All vectors were titrated on HEK293 cells infected in serial dilution on triplicate columns of 96-well plates for either GFP fluorescence or X-gal staining. GFP fluorescence was monitored with Axiovert-25 fluorescent microscope (Carl Zeiss, Germany) and an FITC excitation/emission filter set (Chroma Technology Corp, Rockingham, VT, USA) 2 days post-infection. Cells infected with Ad/C.LacZ were fixed 2 days postinfection with a fixative solution (2% formaldehyde, 0.05% glutaraldehyde in 1 Â PBS) for 5 min at room temperature and then stained overnight at 371C in X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) solution (1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 in 1 Â PBS). The resulting titers were scored as infectious units (IU) per ml. Figure 3 ) served as a positive control for GFP expression. pLAd-CMV served as an empty vector control for transfections. Co-transfection of pRAd 2 2Pb.GFP and pLAd-CMV served as a control for prostate-specific GFP expression (designated as ARR2PB in Figure 3 ). For Ad vector infections, 1 Â 10 4 cells/well were seeded in 96-well plates or 1 Â 10 5 cells/well were seeded in 24-well plates. Seeded cells were infected 3 h post-seeding at MOIs of 0, 10, 50, 100, or 1000. MOI calculations were based on cell numbers at the time of seeding and on Ad vector titers based on IU/ml.
Transfections and infections in vitro
Quantification of GFP expression
In the transfection or infection experiments, GFP fluorescence in cells was visualized 72 or 48 h posttransduction, respectively, using Axiovert-25 fluorescent microscope with an FITC filter set. For quantitative analysis of GFP activity, cells were lysed with 0.5% Triton X-100 in 1 Â PBS. Cell lysates were transferred to 96-well black microtiter plates (BMG Labtechnologies, Offenburg, Germany) and relative GFP fluorescence was measured using a FLUOstart dual fluorescence/absorbance plate reader (BMG Labtechnologies) at excitation 485 nm and emission 520 nm.
RT-PCR
Cells were seeded on 100 mm 2 plates. When cells reached 80-90% confluency, cells were trypsinized and counted. Cells were resuspended in 10 ml serumcontaining medium, infected at MOI 10, and plated onto 100 mm 2 plates. At 2 days post-infection, the media was aspirated and cells were harvested in 1 ml TRI reagent (Sigma-Aldrich, St Louis, MO, USA). RNA was purified according to the manufacturer's instructions. cDNA was synthesized from 1 mg RNA/sample using the RETROscriptt kit (Ambion Inc., Austin, TX, USA) according to the manufacturer's instructions. Following reverse transcription, cDNA was amplified for either GFP or b-actin using GoTaq DNA Polymerase (Promega, Madison, WI, USA) according to the manufacturer's instructions. PCR was performed on the cDNA using the following sense and anti-sense primers: 
